Product
Recombinant human erythropoietin
Aliases
EPO
6 clinical trials
9 indications
Indication
Renal AnemiaIndication
Traumatic Optic NeuropathyIndication
Poor Graft FunctionIndication
Toxic Optic NeuropathyIndication
TherapyIndication
MethylprednisoloneIndication
ErythropoietinIndication
ErythrocytosisIndication
Abnormal ErythropoiesisClinical trial
A Phase Ⅱ Clinical Study on the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Polyethylene Glycol Recombinant Human Erythropoietin Injection (CHO Cell) in Optimal Dose and Administration Regimen for Maintenance Therapy in Patients With Regular Dialysis Renal Anemia.Status: Recruiting, Estimated PCD: 2023-03-17
Clinical trial
Traumatic Optic Neuropathy Treatment Trial 2; Efficacy of Different Doses of Erythropoietin. A Multicenter, Double Blind RCTStatus: Completed, Estimated PCD: 2022-08-06
Clinical trial
Decitabine and Umbilical Cord Blood for Poor Graft Function Post Allogenic Hematopoietic Stem Cell TransplantationStatus: Not yet recruiting, Estimated PCD: 2026-08-01
Clinical trial
Low Dose Decitabine for Poor Graft Function Post Allogenic Hematopoietic Stem Cell TransplantationStatus: Not yet recruiting, Estimated PCD: 2026-07-01
Clinical trial
Effect of Intravenous Methylprednisolone and Intravenous Erythropoietin in Toxic Optic Neuropathies: Randomized Clinical Trial.Status: Recruiting, Estimated PCD: 2024-04-05
Clinical trial
Tracing Changed Production of Red Blood CellsStatus: Completed, Estimated PCD: 2022-12-16